U.S., July 4 -- ClinicalTrials.gov registry received information related to the study (NCT07050160) titled 'Long-term Follow-up Study of Gene Therapy for Arrhythmogenic Cardiomyopathy Due to a Plakophilin-2 Pathogenic Variant' on June 11.
Brief Summary: The primary objective of this Phase 1/2 long-term follow-up (LTFU) study is to assess the long-term safety and tolerability of LX2020 for the treatment of arrhythmogenic cardiomyopathy (ACM) due to a plakophilin-2 gene (PKP2) pathogenic variant (PKP2-ACM).
Study Start Date: Aug., 2025
Study Type: OBSERVATIONAL
Condition:
Arrhythmogenic Cardiomyopathy
PKP2-ACM
PKP2-ARVC
Recruitment Status: NOT_YET_RECRUITING
Sponsor: Lexeo Therapeutics
Published by HT Digital Content Services with per...